Fig. 3.

PET-CT images taken before the start of treatment and after cycle 7 show evidence of antitumor activity. A rapid and durable partial response according to irRC was observed in a 91-year-old man with advanced metastatic acral lentiginous melanoma who had active disease in the liver and multiple lymph nodes when treatment with pembrolizumab at 10 mg/kg Q2W was initiated